---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-005988"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:40:42.776655+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunocore reports 2024 KIMMTRAK net sales of $310M; appoints William Pao to board

## Summary
- KIMMTRAK Q4 net sales $84.1M; full year $310.0M (+30% YoY); net loss $51.1M ($1.02 EPS) vs $55.3M in 2023.
- Ended 2024 with $820.4M cash; repaid $50M Pharmakon loan in Nov 2024.
- Advanced PRAME pipeline: Phase 3 PRISM-MEL-301 enrolled first patient; IMC-P115C and IMC-R117C first doses in Phase 1.
- Appointed Dr. William Pao (CEO of Revelio Therapeutics) as non-executive director effective Feb 25, 2025.
- Expects to present initial HIV data (IMC-M113V) in Q1 2025 and HBV data (IMC-I109V) in H2 2025.

## SEC filing metadata
- accession: 0001140361-25-005988
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/0001140361-25-005988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/ef20044296_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-005988
- JSON: https://secwatch.observer/filing/0001140361-25-005988.json
- Plain text: https://secwatch.observer/filing/0001140361-25-005988.txt

## Key facts
- Executive change
  William Pao was appointed as Director at Immunocore Holdings plc.
  - Action: appointed
  - Role: Director
  source text: the Board appointed William Pao, M.D., Ph.D. to serve as a Class II director of the Company, effective February 25, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671927/000114036125005988/0001140361-25-005988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.